These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34237323)

  • 1. Granulomatous vasculitis after the AstraZeneca anti-SARS-CoV-2 vaccine.
    Gillion V; Jadoul M; Demoulin N; Aydin S; Devresse A
    Kidney Int; 2021 Sep; 100(3):706-707. PubMed ID: 34237323
    [No Abstract]   [Full Text] [Related]  

  • 2. A case of ANCA-associated vasculitis after AZD1222 (Oxford-AstraZeneca) SARS-CoV-2 vaccination: casualty or causality?
    Villa M; Díaz-Crespo F; Pérez de José A; Verdalles Ú; Verde E; Almeida Ruiz F; Acosta A; Mijaylova A; Goicoechea M
    Kidney Int; 2021 Oct; 100(4):937-938. PubMed ID: 34416184
    [No Abstract]   [Full Text] [Related]  

  • 3. When is it reasonable to extrapolate during a pandemic?: The case of broad UK labeling for AstraZeneca COVID-19 vaccine.
    Dal-Ré R; Banzi R
    Eur J Intern Med; 2021 May; 87():1-2. PubMed ID: 33810939
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous small-vessel vasculitis following COVID-19 vaccine.
    Kar BR; Singh BS; Mohapatra L; Agrawal I
    J Cosmet Dermatol; 2021 Nov; 20(11):3382-3383. PubMed ID: 34529877
    [No Abstract]   [Full Text] [Related]  

  • 5. In adults, the Oxford/AstraZeneca vaccine had 70% efficacy against COVID-19 >14 d after the 2nd dose.
    Chagla Z
    Ann Intern Med; 2021 Mar; 174(3):JC29. PubMed ID: 33646835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxford-AstraZeneca COVID-19 vaccine efficacy.
    Knoll MD; Wonodi C
    Lancet; 2021 Jan; 397(10269):72-74. PubMed ID: 33306990
    [No Abstract]   [Full Text] [Related]  

  • 7. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
    Neurosciences (Riyadh); 2021 Apr; 26(2):222-223. PubMed ID: 33814381
    [No Abstract]   [Full Text] [Related]  

  • 8. Thromboaspiration and fibrinolysis infusion for portomesenteric thrombosis after AstraZeneca COVID-19 vaccine administration.
    Barral M; Arrive L; El Mouhadi-Barnier S; Cornelis FH
    Intensive Care Med; 2021 Sep; 47(9):1034-1036. PubMed ID: 34132839
    [No Abstract]   [Full Text] [Related]  

  • 9. Amyotrophic neuralgia secondary to Vaxzevri (AstraZeneca) COVID-19 vaccine.
    Crespo Burillo JA; Loriente Martínez C; García Arguedas C; Mora Pueyo FJ
    Neurologia (Engl Ed); 2021 Sep; 36(7):571-572. PubMed ID: 34330677
    [No Abstract]   [Full Text] [Related]  

  • 10. Leukocytoclastic vasculitis after exposure to COVID-19 vaccine.
    Fritzen M; Funchal GDG; Luiz MO; Durigon GS
    An Bras Dermatol; 2022; 97(1):118-121. PubMed ID: 34836739
    [No Abstract]   [Full Text] [Related]  

  • 11. Sustained COVID-19 vaccine willingness after safety concerns over the Oxford-AstraZeneca vaccine.
    Sønderskov KM; Dinesen PT; Østergaard SD
    Dan Med J; 2021 Mar; 68(5):. PubMed ID: 33870886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia: A missed opportunity for a rapid return of experience.
    Geeraerts T; Montastruc F; Bonneville F; Mémier V; Raposo N;
    Anaesth Crit Care Pain Med; 2021 Aug; 40(4):100889. PubMed ID: 34033927
    [No Abstract]   [Full Text] [Related]  

  • 14. COVAX Statement on WHO emergency use listing for AstraZeneca/Oxford COVID-19 vaccine.
    Saudi Med J; 2021 Mar; 42(3):344-345. PubMed ID: 33632917
    [No Abstract]   [Full Text] [Related]  

  • 15. Cutaneous lymphocytic vasculitis after administration of COVID-19 mRNA vaccine.
    Vassallo C; Boveri E; Brazzelli V; Rampino T; Bruno R; Bonometti A; Gregorini M
    Dermatol Ther; 2021 Sep; 34(5):e15076. PubMed ID: 34327795
    [No Abstract]   [Full Text] [Related]  

  • 16. Possible case of mRNA COVID-19 vaccine-induced small-vessel vasculitis.
    Bostan E; Zaid F; Akdogan N; Gokoz O
    J Cosmet Dermatol; 2022 Jan; 21(1):51-53. PubMed ID: 34705320
    [No Abstract]   [Full Text] [Related]  

  • 17. A localised vasculitic-like skin rash following the second dose of COVID-19 vaccine.
    Abobaker A; Idris MA; Ogunjimi O
    Int J Infect Dis; 2022 Jan; 114():29-30. PubMed ID: 34742927
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefits and risks associated with different uses of the COVID-19 vaccine Vaxzevria: a modelling study, France, May to September 2021.
    Tran Kiem C; Andronico A; Bosetti P; Paireau J; Alter L; Boëlle PY; Fontanet A; Lévy-Bruhl D; Cauchemez S
    Euro Surveill; 2021 Jul; 26(26):. PubMed ID: 34212840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Temporary suspension of AstraZeneca's vaccine; a reconstruction].
    Maas DPMSM; Kramers C; Smit HJCA; Middeldorp S; Helsloot I
    Ned Tijdschr Geneeskd; 2021 Apr; 165():. PubMed ID: 33914428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.